Alto Neuroscience Inc
ANRO
Company Profile
Business description
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Contact
650 Castro Street
Suite 450
Mountain ViewCA94041
USAT: +1 650 200-0412
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
76
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,043.90 | 482.20 | 6.38% |
| CAC 40 | 6,896.91 | 203.51 | -2.87% |
| DAX 40 | 19,670.88 | 609.38 | -3.00% |
| Dow JONES (US) | 40,608.45 | 62.52 | 0.15% |
| FTSE 100 | 7,705.87 | 204.66 | -2.59% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 17,124.97 | 574.37 | 3.47% |
| Nikkei 225 | 34,287.79 | 2,573.76 | 8.12% |
| NZX 50 Index | 12,308.81 | 502.26 | 4.25% |
| S&P 500 | 5,456.90 | 474.13 | 9.52% |
| S&P/ASX 200 | 7,842.90 | 467.90 | 6.34% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |